103 related articles for article (PubMed ID: 11173931)
21. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
22. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
Mark TL; McKenzie RS; Fastenau J; Piech CT
Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human erythropoietin therapy in the surgical setting and applications in oncology.
Goodnough LT
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):98-102. PubMed ID: 1928088
[TBL] [Abstract][Full Text] [Related]
24. Erythropoietin and the anemia of cancer.
Beguin Y
Acta Clin Belg; 1996; 51(1):36-52. PubMed ID: 8669161
[TBL] [Abstract][Full Text] [Related]
25. Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO).
Burk R
Med Hypotheses; 2007; 69(6):1200-4. PubMed ID: 17493766
[TBL] [Abstract][Full Text] [Related]
26. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
27. Epoietin alfa (EPO) for anemia.
Hanna L
BETA; 1998 Jul; ():40, 42. PubMed ID: 11365562
[TBL] [Abstract][Full Text] [Related]
28. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
[TBL] [Abstract][Full Text] [Related]
29. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
Sinnassamy P; Andre JL; Treize G; Leroy B
Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.
van der Putten K; Braam B; Jie KE; Gaillard CA
Nat Clin Pract Nephrol; 2008 Jan; 4(1):47-57. PubMed ID: 18094727
[TBL] [Abstract][Full Text] [Related]
31. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
32. Contemporary uses of erythropoietin in pregnancy: a literature review.
Sienas L; Wong T; Collins R; Smith J
Obstet Gynecol Surv; 2013 Aug; 68(8):594-602. PubMed ID: 23921673
[TBL] [Abstract][Full Text] [Related]
33. [Erythropoietinin oncologic therapy -- what so we know about the risks?].
Leo C; Fink D
Praxis (Bern 1994); 2011 Oct; 100(20):1239-46. PubMed ID: 21971618
[TBL] [Abstract][Full Text] [Related]
34. Erythropoietin therapy in cancer patients.
Doweiko JP; Goldberg MA
Oncology (Williston Park); 1991 Aug; 5(8):31-7; discussion 38, 43-4. PubMed ID: 1834151
[TBL] [Abstract][Full Text] [Related]
35. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
[TBL] [Abstract][Full Text] [Related]
36. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
[TBL] [Abstract][Full Text] [Related]
37. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
39. [Erythropoietin].
Kubanek B; Rich I; Noé G
Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():46-50. PubMed ID: 7531047
[TBL] [Abstract][Full Text] [Related]
40. [Erythropoietin: a study of its use in oncohematology].
Fernández Martín JM; Villa Rubio A; Cameán Fernández M; Borrero Rubio JM; Martínez Díaz C; Díaz Navarro J; Moreno Sánchez FC; Serrano Ruiz FJ
Farm Hosp; 2004; 28(1):20-8. PubMed ID: 15012175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
